These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8630097)

  • 1. Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators.
    Renton FJ; Jeitner TM
    Biochem Pharmacol; 1996 Jun; 51(11):1553-61. PubMed ID: 8630097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle.
    Brodie C; Siriwardana G; Lucas J; Schleicher R; Terada N; Szepesi A; Gelfand E; Seligman P
    Cancer Res; 1993 Sep; 53(17):3968-75. PubMed ID: 8358725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
    Darnell G; Richardson DR
    Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines.
    Hoyes KP; Hider RC; Porter JB
    Cancer Res; 1992 Sep; 52(17):4591-9. PubMed ID: 1511427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.
    Kicic A; Chua AC; Baker E
    Br J Pharmacol; 2002 Mar; 135(6):1393-402. PubMed ID: 11906952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endosomal and lysosomal effects of desferrioxamine: protection of HeLa cells from hydrogen peroxide-induced DNA damage and induction of cell-cycle arrest.
    Doulias PT; Christoforidis S; Brunk UT; Galaris D
    Free Radic Biol Med; 2003 Oct; 35(7):719-28. PubMed ID: 14583336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of different exposures to desferrioxamine on neuroblastoma cell lines.
    Valle P; Timeus F; Piglione M; Rosso P; di Montezemolo LC; Crescenzio N; Marranca D; Ramenghi U
    Pediatr Hematol Oncol; 1995; 12(5):439-46. PubMed ID: 8519628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines.
    Rakba N; Loyer P; Gilot D; Delcros JG; Glaise D; Baret P; Pierre JL; Brissot P; Lescoat G
    Carcinogenesis; 2000 May; 21(5):943-51. PubMed ID: 10783316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D; Ponka P; Baker E
    Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
    Gao J; Richardson DR
    Blood; 2001 Aug; 98(3):842-50. PubMed ID: 11468187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.
    Brard L; Granai CO; Swamy N
    Gynecol Oncol; 2006 Jan; 100(1):116-27. PubMed ID: 16203029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.
    Kicic A; Chua AC; Baker E
    Anticancer Drug Des; 2001; 16(4-5):195-207. PubMed ID: 12049478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase.
    Green DA; Antholine WE; Wong SJ; Richardson DR; Chitambar CR
    Clin Cancer Res; 2001 Nov; 7(11):3574-9. PubMed ID: 11705879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of iron chelators on proliferation and iron uptake in hepatoma cells.
    Kicic A; Chua AC; Baker E
    Cancer; 2001 Dec; 92(12):3093-110. PubMed ID: 11753989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activities of four chelating agents against human neuroblastoma cells.
    Shen L; Zhao HY; Du J; Wang F
    In Vivo; 2005; 19(1):233-6. PubMed ID: 15796180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism of antiproliferative effect of desferrioxamine on human hepatoma cell lines.
    Kim DY; Kim WH; Kang JK; Park S; Kwon OH
    Yonsei Med J; 1994 Mar; 35(1):62-71. PubMed ID: 8009898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferoxamine inhibition of human neuroblastoma viability and proliferation.
    Becton DL; Bryles P
    Cancer Res; 1988 Dec; 48(24 Pt 1):7189-92. PubMed ID: 3191493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
    Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
    ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron chelators induce apoptosis in proliferating cells.
    Hileti D; Panayiotidis P; Hoffbrand AV
    Br J Haematol; 1995 Jan; 89(1):181-7. PubMed ID: 7833261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.